An Open Randomized Phase I Study Evaluating Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Infants Born to HIV-1/2-uninfected Mothers
Latest Information Update: 24 Jun 2022
At a glance
- Drugs HIV DNA vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 02 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Aug 2011 Additional trial location (South Africa) identified as reported by Pan African Clinical Trials Registry.
- 15 Jun 2010 Actual initiation date added to 1 Nov 2009 as reported by ClinicalTrials.gov.